EGFR and non-small cell lung carcinoma: This is particularly relevant in patients with NSCLC, where EGFR mutations and ALK gene fusions are found in approximately 30% and 4%–6% of patients, respectively.17–19 Gefitinib, an EGFR TKI, was granted an accelerated FDA approval in 2003, for treatment of locally advanced or metastatic NSCLC refractory to platinum and docetaxel.